Press Release

Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic

Recurring revenue stable overall

11 December 2020

Jena, Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec generated revenue of €1,335.5m in fiscal year 2019/20 (prior year: €1,459.3m), a decline of -8.5% (adjusted for currency effects: -8.7%) year on year. Earnings before interest and taxes (EBIT) decreased to €177.6m (prior year: €264.7m). The EBIT margin was 13.3% (prior year: 18.1%).

“Fiscal year 2019/20 was entirely dominated by the COVID-19 pandemic,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “Our top priority was the close cooperation with our customers and protecting our employees. We responded quickly to the short-term decline in demand, secured our production and delivery capacity and adjusted costs. A stable overall surgical consumables business also helped to limit the decline in revenue and profit.”

Both strategic business units report decline in revenue

Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -7.3% in fiscal year 2019/20 (adjusted for currency effects: -7.5%), to €990.6m (prior year: €1,068.6m). Revenue in the Microsurgery SBU decreased by -11.7% (adjusted for currency effects: -12.1%), to €344.8m (prior year: €390.7m). Recurring revenue from consumables, implants and service accounted for a 38.8% share of revenue – a new high after 33.9% in the prior year.

Stable performance in APAC1 region – significant declines in EMEA2 and Americas

Revenue in the EMEA region decreased by -13.1% (adjusted for currency effects: -12.7%), to €362.4m (prior year: €417.1m). Declines were recorded particularly in the markets worst affected by the COVID-19 pandemic in Western Europe, the UK, Turkey and the Middle East region. There was a perceptible recovery in Germany toward the end of the reporting period.

The Americas region recorded a revenue decline of -13.2% (adjusted for currency effects: -13.8%), to €384.0m (prior year: €442.5m). In the third quarter, revenue decreased significantly in the USA and Brazil in particular, after both had achieved growth at the start of the fiscal year.

With revenue of €589.0m, the APAC region almost reached the prior-year figure of €599.7m (-1.8%; adjusted for currency effects: -2.3%), bolstered by a robust recovery in China and South Korea in the second half of the year. The markets of Japan, India and Southeast Asia, on the other hand, showed a decline.

Operating result below prior year

The operating result (earnings before interest and taxes: EBIT) decreased to €177.6m in fiscal year 2019/20 (prior year: €264.7m). The EBIT margin decreased to 13.3% (prior year: 18.1%). Adjusted for special effects, this resulted in an increase to 13.8% (prior year: 18.5%). Earnings per share fell to €1.37 (prior year: €1.79).

Carl Zeiss Meditec broadly expects a recovery of its markets in fiscal year 2020/21 and thereby a return to growth in revenue and EBIT. Carl Zeiss Meditec generally expects to see a recovery of the markets in fiscal year 2020/21 and thus a return to renewed growth in revenue and EBIT. In light of the current COVID-19 infection rates in Europe and North America, however, it cannot be ruled out that the pandemic may cause further strain at the beginning of the new fiscal year. The Company predicts that the first few months of the new fiscal year 2020/21 will lag behind the corresponding year-ago figures for revenue and EBIT.

  • All figures in €m

    12 months 2019/20

    12 months 2018/19

    Change from prior year

    Change from prior year (adjusted for currency effects)

    Ophthalmology

    990.6

    1,068.6

    -7.3%

    -7.5%

    Microsurgery

    344.8

    390.7

    -11.7%

    -12.1%

    Consolidated

    1,335.5

    1,459.3

    -8.5%

    -8.7%

  • All figures in €m

    12 months 2019/20

    12 months 2018/19

    Change from prior year

    Change from prior year (adjusted for currency effects)

    EMEA

    362.4

    417.1

    -13.1%

    -12.7%

    Americas

    384.0

    442.5

    -13.2%

    -13.8%

    APAC

    589.0

    599.7

    -1.8%

    -2.3%

    Consolidated

    1,335.5

    1,459.3

    -8.5%

    -8.7%

Additional information regarding this publication and the analyst conference call on FY 2019/20 results are available at https://www.zeiss.com/meditec-ag/investor-relations/financial-calendar/conference-calls.html.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

 


Share this article

  • 1

    Asia/Pacific

  • 2

    Europe, Middle East, Africa